Related Topics News -

     
 Title only   |   Print 
     
瑞博生物申請於歐盟開展RBD3133治療肥胖症一期臨床試驗

2026-10-08T  
瑞博生物回購17.18萬股 涉資935萬元

2026-09-14T  
瑞博生物料中期收入按年增最多3.2倍

2026-07-30T  
瑞博生物產品VORTOSIRAN針對SPAF的2B期臨床試驗獲EMA批准

2026-07-29T  
瑞博生物核心產品VORTOSIRAN針對CAD的2A期研究結果積極

2026-07-22T  
瑞博生物獲聯席CEO增持1.32萬股

2026-07-06T  
瑞博生物與Madrigal合作首個候選藥物選定里程碑已達成

2026-07-02T  
《大行》招商證券國際首予瑞博生物「增持」評級 目標價105元

2026-06-22T  

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.